| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $30.5M | -15.0% | +4.3% |
| SG&A Expense | $8.3M | -3.8% | -13.6% |
| Operating Income | -$38.7M | +12.8% | +0.1% |
| Net Income | -$36.8M | +12.6% | -6.7% |
| EPS (Basic) | -$0.85 | +12.4% | -6.2% |
| EPS (Diluted) | -$0.85 | +12.4% | -6.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $34.2M | -36.1% | -67.4% |
| Short-term Investments | $137.0M | -13.4% | -36.9% |
| Current Assets | $174.9M | -18.4% | -46.2% |
| Total Assets | $187.2M | -17.4% | -44.8% |
| Current Liabilities | $33.9M | -14.9% | +9.3% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$120.2M | — | — |
| Capital Expenditures | $6K | — | — |
| Investing Cash Flow | $57.3M | — | — |
| Financing Cash Flow | $425K | — | — |
| Free Cash Flow | -$120.2M | — | — |
| $35.2M |
| -16.4% |
| -3.5% |
| Stockholders' Equity | $151.9M | -17.6% | -49.8% |